IM96 CAR-T cells
Alternative Names: Anti-GUCY2C chimeric antigen receptor T-cell; IM96; IM96 CAR-T cells - Beijing Immunochina Medical Science and TechnologyLatest Information Update: 13 Jul 2024
At a glance
- Originator Beijing Immunochina Medical Science and Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Colorectal cancer; Digestive system neoplasms; Pancreatic cancer
Most Recent Events
- 31 May 2024 Updated efficacy and adverse event data from a phase I trial in Digestive system neoplasms presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 20 Oct 2023 Efficacy and adverse events data from phase I trial in Pancreatic cancer, Colorectal cancer and Digestive system neoplasms presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 10 Mar 2022 Phase-I clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT05287165)